Biliverdin Reductase (BVR) Peptides That Inhibit PCK-delta for the Potential Treatment of Cancer and Inflammation

Brief Description

Applications:

Dr. M. Maines is a leading expert in BVR research and has uncovered many applications for this enzyme. In this invention she has linked BVR to modulation of PKC and found potent inhibitory peptides that may have utility in both understanding and treating cancer. A multiplicity of functions has been ascribed to PKC. Recurring themes are that PKC is involved in receptor desensitization, in modulating membrane structure events, in regulating transcription, in mediating immune responses, in regulating cell growth, and in learning and memory. These functions are achieved by PKC mediated phosphorylation of other proteins.

Advantages: 

This is the first time BVR and PKCs have been linked and it opens up many avenues for therapeutic discovery. The peptides will eventually be tested in animals for anti-cancer activity.

 

Patent Information:
Title Country Patent No. Issued Date
Use of Human Biliverdin Reductase and Fragments Thereof Protein Kinase C-Delta and ERK Related Conditions United States 9,078,913 7/14/2015
Category(s):
Therapeutic
For Information, Contact:
Weimin Kaufman
Licensing Manager
University of Rochester
585.276.6608
weimin.kaufman@rochester.edu
Inventors:
Mahin Maines
Keywords:
Cancer
Oncology
Peptide
Protein
Target Validation
Therapy